Accueil   Diary - News   All news CEA-Leti breakthrough opens path to new vaccine for HIV using lipid-nanoparticle-delivery technology

CEA-Leti breakthrough opens path to new vaccine for HIV using lipid-nanoparticle-delivery technology

 

GRENOBLE, France – Feb. 27, 2019 – Leti, a research institute of CEA Tech, in collaboration with CEA's Fundamental Research Division, has developed a new vaccine approach for HIV based on engineered lipid nanoparticles that deliver p24 - a viral protein that is key to an HIV vaccine- and optimize the CpG adjuvant's effect.

 

Until now, p24-based vaccines have shown limited effectiveness because of an insufficient immune response to this antigen in HIV patients. Based on its Lipidots® delivery platform, CEA-Leti's new approach improves immunogenicity against the p24 HIV protein by loading it and an immunostimulant agent onto nanostructured lipid carriers (NLCs). This may be a first step for a new HIV vaccine that also would include additional components of the virus.

 

Read the complete press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree